[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Barrett et al., 2008 - Google Patents

Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier

Barrett et al., 2008

Document ID
8392003747730166237
Author
Barrett A
Dehghani F
Foster N
Publication year
Publication venue
Pharmaceutical research

External Links

Snippet

Purpose The purpose of this study was to increase the dissolution rate of the poorly water soluble, antifungal drug Itraconazole. Methods Itraconazole was successfully micronized using both the gas antisolvent (GAS) and aerosol solvent extraction systems (ASES) using …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Similar Documents

Publication Publication Date Title
Majerik et al. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation
Barrett et al. Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier
Esfandiari et al. Ampicillin nanoparticles production via supercritical CO 2 gas antisolvent process
Tandya et al. Micronization of cyclosporine using dense gas techniques
Caliceti et al. Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques
Khadka et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability
Muhrer et al. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug–polymer solid dispersions
Yasuji et al. Particle design of poorly water-soluble drug substances using supercritical fluid technologies
Wang et al. Polymer coating/encapsulation of nanoparticles using a supercritical anti-solvent process
US8852644B2 (en) Method and device for producing microparticles or nanoparticles
Varshosaz et al. Dissolution enhancement of gliclazide using in situ micronization by solvent change method
Duarte et al. Preparation of ethyl cellulose/methyl cellulose blends by supercritical antisolvent precipitation
Costa et al. Supercritical antisolvent precipitation of PHBV microparticles
Obaidat et al. Using supercritical fluid technology (SFT) in preparation of tacrolimus solid dispersions
Zhang et al. Nanonization of megestrol acetate by liquid precipitation
Montes et al. Polymer and ampicillin co-precipitation by supercritical antisolvent process
Xu et al. Design and evaluation of novel solid self-nanodispersion delivery system for andrographolide
Reverchon et al. Supercritical fluids based techniques to process pharmaceutical products difficult to micronize: Palmitoylethanolamide
Adami et al. Supercritical Assisted Atomization for the production of curcumin-biopolymer microspheres
Akbari et al. Generation and precipitation of paclitaxel nanoparticles in basil seed mucilage via combination of supercritical gas antisolvent and phase inversion techniques
Tandya et al. Supercritical fluid micronization techniques for gastroresistant insulin formulations
Coty et al. Use of Spray Flash Evaporation (SFE) technology to improve dissolution of poorly soluble drugs: Case study on furosemide nanocrystals
Liparoti et al. Supercritical assisted atomization: Polyvinylpyrrolidone as carrier for drugs with poor solubility in water
Lim et al. Amorphization of pharmaceutical compound by co-precipitation using supercritical anti-solvent (SAS) process (Part I)
Bakhbakhi et al. Precipitation of Ibuprofen Sodium using compressed carbon dioxide as antisolvent